ライフサイエンスコーパス: DTPA

1 (DTPA)(n)-trastuzumab-(IRDye800)(m) showed significantly

2 DTPA-extractable Zn in soils grown with IR69428 was posi

3 ow was determined by pretreatment indium-111-DTPA studies.

4 hyldiethylenetriamine pentaacetic acid (1B4M-DTPA), bearing either an isothiocyanate or a succinimidy

5 paration of a novel maleimide analog of 1B4M-DTPA from a key synthetic intermediate aniline derivativ

6 other hand, we found that the agent bis-5HT-DTPA-Gd utilizes both mechanisms when activated.

7 extremes in either oligomerization (mono-5HT-DTPA-Gd) or protein-binding in their activation mechanis

8 IDDS system of the drug, radiotracer (99mTc-DTPA) solution was injected into the pump reservoir.

9 removed from EP-2104R by a challenge with a DTPA based ligand, while the commercial contrast agents

10 Panitumumab was conjugated to CHX-A''-DTPA and radiolabeled with (86)Y.

11 adiolabeled with (177)Lu through the CHX-A''-DTPA chelator.

12 gated to a 100-nm diameter liposomal-CHX-A''-DTPA construct, upon which the rat HER2/neu reactive ant

13 iethylene-triamine-pentaacetic acid (CHX-A''-DTPA)/linker construct to the EGFR-directed antibody cet

14 (a) 19.2 MBq (520 muCi) of liposome-CHX-A''-DTPA-(213)Bi, (b) 19.2 MBq of liposome-CHX-A''-DTPA-(213

15 PA-(213)Bi, (b) 19.2 MBq of liposome-CHX-A''-DTPA-(213)Bi-7.16.4, (c) 4.44 MBq (120 muCi) of (213)Bi-

16 d (d) cold (nonradioactive) liposome-CHX-A''-DTPA-7.16.4 as control.

17 (90)Y-Y-CHX-A''-DTPA-cetuximab affected cell survival through the induct

18 Exposure to (90)Y-Y-CHX-A''-DTPA-cetuximab also resulted in efficient cell killing,

19 ted radioimmunotherapy using (90)Y-Y-CHX-A''-DTPA-cetuximab appears to be a powerful tool that can be

20 antibody cetuximab to yield (90)Y-Y-CHX-A''-DTPA-cetuximab with a specific activity of approximately

21 When cells were exposed to (90)Y-Y-CHX-A''-DTPA-cetuximab, the number of induced DSBs increased lin

22 demonstrates the potential of (86)Y-CHX-A''-DTPA-panitumumab for quantitative noninvasive PET of HER

23 (86)Y-CHX-A''-DTPA-panitumumab was routinely prepared with a specific

24 0.005 M diethylenetriaminepentaacetic acid (DTPA) (pH 7.6) extraction fluid at selected times over 3

25 dolinium-diethylenetriaminepentaacetic acid (DTPA) as a contrast agent for MR imaging and (18)F-FDG,

26 A x anti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)),

27 such as diethylenetriaminepentaacetic acid (DTPA) derivatives, dissociation-enhanced lanthanide fluo

28 CHX-A''-diethylenetriaminepentaacetic acid (DTPA) or benzyl-DTPA conjugated to a recombinant immunog

29 ition of diethylenetriaminepentaacetic acid (DTPA) to allow (111)In labeling or the fluorophore Cy3.

30 (99m)Tc-diethylenetriaminepentaacetic acid (DTPA) was also estimated as a reference.

31 (111)In-diethylenetriaminepentaacetic acid (DTPA) with the standardized (99m)Tc-labeled solid meal.

32 d (NTA), diethylenetriaminepentaacetic acid (DTPA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra

33 dolinium-diethylenetriaminepentaacetic acid (DTPA), bolus injection of (18)F-FDG, bolus injection of

34 -(111)In-diethylenetriaminepentaacetic acid (DTPA)-anti-PD-L1-to identify PD-L1-positive tumors in vi

35 ium (Gd)-diethylenetriaminepentaacetic acid (DTPA)-bis(stearylamide) and DiI dye were used to label m

36 (111)In-diethylenetriaminepentaacetic acid (DTPA)-labetuzumab-IRDye800CW can detect pulmonary microm

37 (111)In-diethylenetriaminepentaacetic acid (DTPA)-MN-14-IRDye 800CW and performed 4 studies on mice

38 (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implem

39 (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the nuclear m

40 -CHX-A''-diethylenetriaminepentaacetic acid (DTPA)-panitumumab for quantitative PET of HER1-expressin

41 (111)In-diethylenetriaminepentaacetic acid (DTPA)-Tyr3-octreotate.

42 gadolinium-diethyltriaminepentaacetic acid (DTPA) were tested in ApoE-/- and WT mice by using in viv

43 213)Bi-diethylene triamine pentaacetic acid (DTPA) in mouse models was performed.

44 agent diethylene triamine pentaacetic acid (DTPA) significantly reduced H2O2 generation.

45 TA) and diethylenetriamine pentaacetic acid (DTPA) were found to increase Cu translocation to shoot t

46 111)In-diethylene triamine pentaacetic acid (DTPA), a small hydrophilic molecule, was cleared rapidly

47 ane [HT]-diethyneletriaminepentaacetic acid [DTPA]-gadolinium or indium 111-bis-5-HT-DTPA, respective

48 168 h after injection of (111)In-[Lys40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to

49 ically tested reference compound [Lys40-(AHX-DTPA-111In)NH2]exendin-4 and, thus, represent potential

50 ndin-4 was comparable to that of [Lys40-(AHX-DTPA-111In)NH2]exendin-4 at 1-48 h after injection.

51 -(AHX-DFO-89Zr)NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 performed similarly well.

52 xperiments, clinically evaluated [Lys40-(AHX-DTPA-111In)NH2]exendin-4 was used as a reference compoun

53 ndustry "gold standards" DOTA (N(4)O(4)) and DTPA (N(3)O(5)).

54 A dextranated and DTPA-modified magnetofluorescent 20-nm nanoparticle was

55 La and HT29 cancer cells compared to DFO and DTPA.

56 improved stability when compared to DOTA and DTPA over 24 h.

57 id increased membrane damage, while EDTA and DTPA had transient effects.

58 Novel chelates PIP-DTPA, AZEP-DTPA, NETA, NPTA, and PIP-DOTA were synthesized and eval

59 3Gd-labeled complexes, Gd(PIP-DTPA), Gd(AZEP-DTPA), Gd(PIP-DOTA), Gd(NETA), and Gd(NPTA), was assesse

60 enetriaminepentaacetic acid (DTPA) or benzyl-DTPA conjugated to a recombinant immunoglobulin G (IgG)

61 frames after injection of 7.4 MBq of (213)Bi-DTPA showed renal uptake and urinary clearance, visualiz

62 d with trastuzumab or human IgG followed by (DTPA)(n)-trastuzumab-(IRDye800)(m) and examined under a

63 nificant improvement to the acyclic chelator DTPA.

64 taacetate-tetra [DTPA]-A20FMDV2) or control (DTPA-A20FMDVran) peptide by nanoSPECT/CT imaging.

65 , the hybrid labeled somatostatin analog Cy5-DTPA-Tyr(3)-octreotate (DTPA is diethylene triamine pent

66 constant value was 387.7 +/- 97.9 nM for Cy5-DTPA-Tyr(3)-octreotate, whereas it was 120.5 +/- 18.1 nM

67 tate to 1.32% +/- 0.02% applied dose for Cy5-DTPA-Tyr(3)-octreotate.

68 or affinity and internalization rate for Cy5-DTPA-Tyr(3)-octreotate.

69 affinity and internalization capacity of Cy5-DTPA-Tyr(3)-octreotate were assessed in vitro.

70 x m734) (40 mg/m(2)), followed by (131)I-di-DTPA-indium bivalent hapten (1.8 GBq/m(2)) 4-6 d later.

71 thylenetriaminepentaacetic acid dianhydride (DTPA) and IRDye 800CW molecules bound per trastuzumab mo

72 heir activation mechanism (bis-o-dianisidine-DTPA-Gd).

73 s measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations.

74 The Gd-EOB-DTPA in combination with regular T2-weighted MRCP may be

75 system and thus a decision to inject Gd-EOB-DTPA was taken.

76 he effect of gadoxetic acid disodium (Gd-EOB-DTPA) on T2 relaxation times and apparent diffusion coef

77 -diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA) with dynamic contrast-enhanced MR imaging (DCEMRI)

78 The accuracy of Gd-EOB-DTPA-3T-MR significantly improves for lesions <20 mm.

79 ERIAL/73 patients underwent DCECT and Gd-EOB-DTPA-3T-MR.

80 ll HCA subtypes were hypoenhancing at Gd-EOB-DTPA-enhanced MR imaging in the hepatobiliary phase and

81 nt before and after administration of Gd-EOB-DTPA.

82 d after intravenous administration of Gd-EOB-DTPA.

83 A slower release rate of EPI(DTPA)(111)In than EPI(Tyr)(125)I was observed.

84 The results show that Eu-DTPA-monoamide complex 18b, which contains a quinoxanlin

85 ine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTPA Pearson R, 0.97; P = .003).

86 ibed iron (Fe) chelates of pentetic acid (Fe-DTPA) and of trans-cyclohexane diamine tetraacetic acid

87 The volume transfer constant values for Fe-DTPA and Fe-tCDTA in the same tumors correlated well wit

88 R imaging with intravenous application of Fe-DTPA or Fe-tCDTA on day 1 and DCE MR imaging in the same

89 duced from 33.76% +/- 1.22% applied dose for DTPA-Tyr(3)-octreotate to 1.32% +/- 0.02% applied dose f

90 eotate, whereas it was 120.5 +/- 18.1 nM for DTPA-Tyr(3)-octreotate.

91 ly bound to an albumin (BSA)-Gd (gadolinium)-DTPA (diethylene triamine penta acetic acid)-biotin MRI

92 conventional liposome containing gadolinium-DTPA-BSA lipid.

93 A to simulate the distribution of gadolinium-DTPA (which represents its partition coefficient in well

94 ssue regions, as defined from the gadolinium-DTPA contrast-enhanced MR images, showed (18)F-NaF uptak

95 micelles and no enhancement using gadolinium-DTPA.

96 spin relaxation agents (5DSA, 16DSA, and Gd(DTPA-BMA)) indicated that the amphipathic alpha-helices

97 ramagnetic relaxation agent, gadodiamide (Gd(DTPA-BMA)).

98 fold more resistant to dissociation than [Gd(DTPA)(H2O)](2-).

99 Gd-DTPA-enhanced infarcts showed high (18)FDG uptake on day

100 um diethylene-triamine penta-acetic acid (Gd-DTPA) as a contrast agent for dynamic contrast-enhanced

101 nium diethylenetrianime pentaacedic acid (Gd-DTPA) bisoleate (BOA) or gadolinium tetraazacyclododecan

102 nium diethylenetriamine pentaacetic acid (Gd-DTPA) enhanced MRI was performed at baseline, 3 hours an

103 MA) were compared with gadopentetic acid (Gd-DTPA) for infarct size determination, contrast-to-noise

104 um-diethylene-triamino-penta-acetic acid (Gd-DTPA) infused in the subconjunctival or intrascleral spa

105 inium diethylenetriaminepentaacetic acid (Gd-DTPA).

106 Immediately after Gd-DTPA administration, a high-signal-intensity rim was obs

107 noise ratio (infarct versus septum) after Gd-DTPA injection peaked at 10 minutes and returned to prei

108 (BRB PS') was determined using MRI after Gd-DTPA injection.

109 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

110 g extravasation of the MRI contrast agent Gd-DTPA was significantly increased in both the sonicated t

111 ent (K(trans)) for an MRI contrast agent (Gd-DTPA) was estimated serially at 4-5 time points ranging

112 breast cancers underwent dynamic albumin-(Gd-DTPA)(30)-enhanced MR imaging followed by an initial dos

113 showed good agreement between Gd-ESMA and Gd-DTPA and were confirmed by ex vivo triphenyltetrazolium

114 d between delayed enhancement imaging and Gd-DTPA between days 7 and 21 (1.8+/- versus 3.8; P=ns), Gd

115 aminoglycan content for sodium iodide and Gd-DTPA only, diffusivity significantly increased for all c

116 +/- standard deviation) with Mn-PyC3A and Gd-DTPA was 476 +/- 77 and 538 +/- 120, respectively (P = .

117 es in diffusivities for sodium iodide and Gd-DTPA, with similar (but not significant) trends for sodi

118 ith various concentrations of Gd-DTPA and Gd-DTPA-BMA, and solutions of PEG 600 which served as a non

119 r diffusivity than sodium diatrizoate and Gd-DTPA.

120 apio anubis; n = 4) by using Mn-PyC3A and Gd-DTPA.

121 h various concentrations of Gd[DTPA-BMA], Gd-DTPA, or GdCl3.

122 mbolic stroke rats, the enhanced areas by Gd-DTPA at 24 h were larger, and the patterns (time, intens

123 dow for HCC chemotherapy, as monitored by Gd-DTPA-enhanced MRI as a noninvasive, clinically applicabl

124 ined for the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to b

125 ed the suprachoroidal layer and delivered Gd-DTPA to the posterior segment.

126 (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pharmacokinetics, a

127 I contrast agent gadopentate dimeglumine [Gd-DTPA(2-)]) is used as an index of the molecular status o

128 the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to be 4.8 +/-

129 The degree of extracapsular Gd-DTPA enhancement was assessed in both conditions using s

130 The transfer coefficient Ktrans for Gd-DTPA and the drug concentrations showed a good linear co

131 nal small-molecule contrast agents, e.g., Gd-DTPA (diethylene triamine pentaacetic acid), used clinic

132 riaminepentaacetic acid gadolinium (III) (Gd-DTPA) and demonstrate their usefulness for MRI.

133 eased the signal intensity from tumors in Gd-DTPA-enhanced MRI.

134 n, and first-pass perfusion (0.03 mmol/kg Gd-DTPA bolus) at stress and rest (4-6 minutes IV adenosine

135 -DTPA enhancement and also in areas of no Gd-DTPA enhancement, which were confirmed histologically to

136 to create contrast was similar to that of Gd-DTPA alone.

137 incubated with various concentrations of Gd-DTPA and Gd-DTPA-BMA, and solutions of PEG 600 which ser

138 Suprachoroidal clearance of Gd-DTPA followed first-order kinetics with an average half-

139 ns failed to produce detectable levels of Gd-DTPA in the back of the eye.

140 Assuming the velocity of Gd-DTPA to be equal to the fluid flow velocity, we used a s

141 Furthermore, MRI-based estimates of Gd-DTPA transport across these barriers might be useful to

142 Distribution and clearance of Gd-DTPA were measured using DCE-MRI.

143 environments show a loss of integrity of Gd-DTPA-BMA analogous to the one observed upon internalizat

144 s also been applied to assess the fate of Gd-DTPA-BMA-loaded liposomes upon their endosomal internali

145 by pulse radiolysis experiments (k((*)OH+Gd-DTPA) = 2.6 +/- 0.2 x 10(9) M(-1) s(-1), k((*)OH+Gd-DTPA

146 2.6 +/- 0.2 x 10(9) M(-1) s(-1), k((*)OH+Gd-DTPA-BMA) = 1.9 +/- 0.7 x 10(9) M(-1) s(-1), k((*)OH+Gd-

147 We injected 0.3 mmol/kg MPO-Gd (or Gd-DTPA as control) and performed magnetic resonance imagin

148 muscle at 9 seconds following Mn-PyC3A or Gd-DTPA injection.

149 Systematic injection of paramagnetic Gd-DTPA did not alter vitreous longitudinal relaxation time

150 gadolinium diethylenetriamine-pentaacid (Gd-DTPA).

151 significantly greater accumulation of PGC-Gd-DTPA-F in the graft area after immune attack initiated b

152 hours after intravenous injections of PGC-Gd-DTPA-F, followed by histologic examination.

153 PGC-Gd-DTPA-F-enhanced MR imaging allows for the in vivo assess

154 Comparing pre- and post-Gd-DTPA images demonstrated minimal choroidal contribution

155 inding was present in all regions showing Gd-DTPA enhancement and also in areas of no Gd-DTPA enhance

156 At 3.0 T, Gd-DTPA-BOA nanoparticles had an ionic r1 of 10.3 L . mmol(

157 455/9, 7 ms, T2 (TR/TE 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

158 nd 3.0% +/- 0.3 with alphavbeta3-targeted Gd-DTPA-BOA nanoparticles (P = .03).

159 se ratio peaked later and was higher than Gd-DTPA (40.8+/-10.4 versus 10.5+/-0.2; P<0.05).

160 and much longer blood retention time than Gd-DTPA in mice.

161 Together, these findings establish that Gd-DTPA-based DCE-MRI can noninvasively visualize tumor IFP

162 xcretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes, 20.

163 l infusion was successful in transporting Gd-DTPA to the posterior segment from an anterior infusion

164 data suggest that one may be able to use Gd-DTPA as a surrogate tracer to estimate DOX delivery to t

165 Contrast enhancement MRI using Gd-DTPA provides a method to detect gross and microscopic H

166 (Gd[DTPA-BMA]; Omniscan) as compared with Gd-DTPA and GdCl3 on the expression and production of cytok

167 al or intrascleral space and infused with Gd-DTPA at 1 and 10 muL/min.

168 We employed contrast enhancement MRI with Gd-DTPA to detect HT in a rat model of embolic stroke treat

169 MA in the postischemic scar compared with Gd-DTPA.

170 Loading of up to 30 wt % Gd-DTPA was achieved, and in vitro release occurred over 5

171 uilibrium (eqMRI) of the Gd(III) chelator Gd.DTPA, via the intraperitoneal route, was used to evaluat

172 etriaminepentaacetic acid bismethylamide (Gd[DTPA-BMA]; Omniscan) as compared with Gd-DTPA and GdCl3

173 incubated with various concentrations of Gd[DTPA-BMA], Gd-DTPA, or GdCl3.

174 Indium 111-labeled bis-5-HT-DTPA was used to determine biodistribution and target lo

175 thylenetriaminepentaacetic acid (Gd-bis-5-HT-DTPA)--were synthesized.

176 cid [DTPA]-gadolinium or indium 111-bis-5-HT-DTPA, respectively).

177 n enzyme on its own in the presence of Eu(II)DTPA, displaying a strong activity in C2H2 reduction whi

178 catalytically active metal center in Eu(II)-DTPA-driven reactions.

179 m(II) diethylenetriaminepentaacetate [Eu(II)-DTPA].

180 21; and a difference in the mean increase in DTPA glomerular filtration rate in the hydroxycarbamide

181 -(111)In-DTPA-Tyr(3)-octreotate and (111)In -DTPA-Tyr(3)-octreotate (6.93 +/- 2.08 and 5.16 +/- 1.27,

182 and optical in vivo imaging of Cy5-(111)In -DTPA-Tyr(3)-octreotate were performed in NET-bearing mic

183 vement to the multiple isomers formed by [In(DTPA)](2-) and [In(DOTA)](-) under the same conditions.

184 abeled meal and 7.4 MBq (0.2 mCi) of (111)In-DTPA in 120 mL of water.

185 performed with 3.7 MBq (0.1 mCi) of (111)In-DTPA in 15 mL of water.

186 th ingestion of 3.7 MBq (0.1 mCi) of (111)In-DTPA in 300 mL of water.

187 gastrointestinal transit study using (111)In-DTPA with the standardized (99m)Tc-labeled solid meal.

188 al-beam radiotherapy, uptake on the [(111)In-DTPA(0)]octreotide scan, tumor load, grade 3-4 hematolog

189 ne metastases that were positive on [(111)In-DTPA(0)]octreotide somatostatin receptor scintigraphy (S

190 design a diagnostic imaging agent, ((111)In-DTPA)(n)-trastuzumab-(IRDye 800CW)(m), that is dual labe

191 ts were injected intravenously with ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) and imaged with SPECT

192 muscle tissue slices indicated that ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) bound only in tumor t

193 Dual-labeled ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) may be an effective d

194 SKBr3-luc xenografts injected with ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m) revealed significantl

195 zumab 24 h before administration of ((111)In-DTPA)(n)-trastuzumab-(IRDye800)(m).

196 cting the mice with IRDye 800CW and ((111)In-DTPA)(p)-IgG-(IRDye800)(q), where "p" and "q" are the st

197 mice injected with IRDye 800CW and ((111)In-DTPA)(p)-IgG-(IRDye800)(q).

198 Results:(111)In-DTPA-anti-PD-L1 (dissociation constant, 0.6 +/- 0.1 nM)

199 Clearance of (111)In-DTPA-anti-PD-L1 from all organs occurred at 144 hours.

200 concentration on the distribution of (111)In-DTPA-anti-PD-L1 in a murine model of aggressive melanoma

201 The distribution of (111)In-DTPA-anti-PD-L1 in tumors as well as the spleen, liver,

202 , thus shifting the concentration of (111)In-DTPA-anti-PD-L1 into the blood stream and potentially in

203 These studies demonstrate that (111)In-DTPA-anti-PD-L1 is capable of identifying tumors that ov

204 ction with streptavidin complexed to (111)In-DTPA-biotin.

205 or biodistribution and NIRF imaging, (111)In-DTPA-D2B-IRDye800CW (2 mug, 0.55 MBq/mouse) was injected

206 micro-SPECT/CT and NIRF imaging with (111)In-DTPA-D2B-IRDye800CW (3 mug, 8.5 MBq/mouse) was performed

207 Dual-labeled (111)In-DTPA-D2B-IRDye800CW enables specific and sensitive detec

208 (111)In-DTPA-D2B-IRDye800CW specifically accumulated in subcutan

209 ndings warrant clinical studies with (111)In-DTPA-D2B-IRDye800CW to improve tumor detection and resec

210 referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.

211 All patients underwent (111)In-DTPA-exendin-4 imaging, 25 patients underwent surgery (w

212 (111)In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinoma

213 (111)In-DTPA-exendin-4 SPECT/CT could provide a good second-line

214 For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [9

215 s identified in separate patients by (111)In-DTPA-exendin-4 SPECT/CT.

216 s40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinomas.

217 d with (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF at the NOAEL, or with unlabeled immun

218 d tumor growth more effectively than (111)In-DTPA-Fab-PEG24-EGF because of a 9.3-fold-higher radiatio

219 ure to (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF or to monospecific (177)Lu- or (111)I

220 ted by (177)Lu-DOTA-Fab-PEG24-EGF or (111)In-DTPA-Fab-PEG24-EGF.

221 ab-PEG24-EGF was more cytotoxic than (111)In-DTPA-Fab-PEG24-EGF.

222 d 3 d after intravenous injection of (111)In-DTPA-labetuzumab-IRDye800CW (10 mug, 25 MBq).

223 jected dose/g) comparable to that of (111)In-DTPA-MN-14 but higher accumulation in the liver.

224 The biodistribution of (111)In-DTPA-MN-14-IRDye 800CW in mice with subcutaneous LS174T

225 g LS174T tumor nodules that received (111)In-DTPA-MN-14-IRDye 800CW, intraperitoneal tumor nodules co

226 e significantly better than those of (111)In-DTPA-OC (87% and 88%, respectively, P = 0.017).

227 OTATATE identified more lesions than (111)In-DTPA-OC and always at least as many.

228 t (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients.

229 th (64)Cu-DOTATATE and SPECT/CT with (111)In-DTPA-OC within 60 d.

230 epentaacetic acid (DTPA)-octreotide ((111)In-DTPA-OC) as a basis for implementing (64)Cu-DOTATATE as

231 (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

232 ected with (64)Cu-DOTATATE than with (111)In-DTPA-OC.

233 ot identified as disease-involved by (111)In-DTPA-OC.

234 is and staging of NETs compared with (111)In-DTPA-octreotide and conventional imaging.

235 patients with negative or equivocal (111)In-DTPA-octreotide findings, (68)Ga-DOTATATE PET identifies

236 fied significantly more lesions than (111)In-DTPA-octreotide scintigraphy (P < 0.001).

237 ative or weakly positive findings on (111)In-DTPA-octreotide scintigraphy to determine whether (68)Ga

238 ative and 16 equivocal for uptake on (111)In-DTPA-octreotide scintigraphy underwent (68)Ga-DOTATATE P

239 d similar tumor uptake values of Cy5-(111)In-DTPA-Tyr(3)-octreotate and (111)In -DTPA-Tyr(3)-octreota

240 and compared with the performance of (111)In-DTPA-Tyr(3)-octreotate.

241 emonstrated that the tumor uptake of (111)In-DTPA-Tyr3-octreotate was not significantly different (P

242 Conversely for IR68144, DTPA-extractable Zn was positively correlated only with

243 nzyl-diethylenetriaminepentaacetic acid (ITC-DTPA) and subsequently radiolabeled with (111)In.

244 these cells with an affinity similar to its DTPA analogue.

245 In vivo CLI and SPECT imaging of (177)Lu-DTPA-11B6 uptake was performed on NMRI and BALB/c nude m

246 reas JVZ-007-cys was conjugated to maleimide-DTPA via the C-terminal cysteine.

247 (99m)Tc-DTPA-succinyl-polylysine (2 microg; DTPA is diethylenetriaminepentaacetic acid) were injecte

248 As more DTPA is attached, the [M+H](+) peak of DTPA-IgG becomes

249 the DTPA attached per IgG increased as more DTPA was attached.

250 necessary to thoroughly remove nonconjugated DTPA from the sample.

251 atostatin analog Cy5-DTPA-Tyr(3)-octreotate (DTPA is diethylene triamine pentaacetic acid) was synthe

252 For the high dose of CuO NPs, the amount of DTPA-extractable Cu in soil increased from 3 wt % immedi

253 rom the difference in the observed masses of DTPA-IgG and nonconjugated IgG divided by the molecular

254 of variation for samples with 2 to 4 mol of DTPA attached per mole of IgG, was 8 to 9%.

255 The average number of moles of DTPA attached per mole of IgG was calculated from the di

256 crease in the heterogeneity in the number of DTPA attached to each molecule of IgG.

257 tration to accurately quantify the number of DTPA conjugated.

258 more DTPA is attached, the [M+H](+) peak of DTPA-IgG becomes broader and noisier.

259 "p" and "q" are the stoichiometric ratios of DTPA and IRDye 800CW bound per IgG antibody, respectivel

260 d to determine the molecular specificity of (DTPA)(n)-trastuzumab-(IRDye800)(m) in vitro in SKBr3 (HE

261 5) between genotypes and Zn fertilization on DTPA (diethylenetriaminepentaacetic acid)-extractable so

262 Mice underwent MPO-Gd- or DTPA-Gd-enhanced MR imaging on days 6, 8, and 10 after i

263 of several diethylenetriamine pentaacetate (DTPA)-monoamide ligands bearing molecular "antennae" to

264 153Gd(NETA), 153Gd(PIP-DTPA), and 153Gd(PIP-DOTA) were found to be stable in hu

265 Novel chelates PIP-DTPA, AZEP-DTPA, NETA, NPTA, and PIP-DOTA were synthesiz

266 ility of the 153Gd-labeled complexes, Gd(PIP-DTPA), Gd(AZEP-DTPA), Gd(PIP-DOTA), Gd(NETA), and Gd(NPT

267 the frequently explored polyaminocarboxylate DTPA.

268 The resulting chelate-Rev (EDTA-Rev, DTPA-Rev, NTA-Rev, and DOTA-Rev) conjugates were used to

269 l)-diethylenetriaminepentaacetic acid (p-SCN-DTPA) via the lysines, whereas JVZ-007-cys was conjugate

270 tion of (18)F-FDG, bolus injection of (99)Tc-DTPA to simulate the distribution of gadolinium-DTPA (wh

271 pectively) in a degree comparable to (99m)Tc-DTPA (2.5 +/- 1.0, 1.5 +/- 0.2, and 0.8 +/- 0.3, respect

272 econd commercially available tracer, (99m)Tc-DTPA (diethylenetriaminepentaacetic acid), had minimal a

273 he promise of [(99m)Tc]TcO(4)(-) and (99m)Tc-DTPA as noninvasive imaging probes for a redox-sensitive

274 ction (glomerular filtration rate by (99m)Tc-DTPA clearance).

275 The mean reference GFR, based on (99m)Tc-DTPA clearance, was 74.9 mL/min/1.73 m(2) +/- 27.7 (stan

276 This procedure was repeated for the (99m)Tc-DTPA group after administration of 96 MBq (2.6 mCi) of t

277 ior of administered (99m)Tc-MAG3 and (99m)Tc-DTPA in experimental animals.

278 hanges were considerably greater for (99m)Tc-DTPA than for (99m)Tc-MAG3.

279 All patients underwent a (99m)Tc-DTPA urinary clearance examination on the same day to ob

280 min, respectively, whereas those for (99m)Tc-DTPA were 10.1 +/- 1 and 35 +/- 4 min, respectively.

281 min, respectively, whereas those of (99m)Tc-DTPA were 3.4 +/- 0.4 and 18.2 +/- 2 min, respectively.

282 diethylenetriamine pentaacetic acid ((99m)Tc-DTPA) is predominantly excreted by glomerular filtration

283 land White rabbits ((99m)Tc-MAG3 and (99m)Tc-DTPA) were used for the renography.

284 The next day, approximately 15.0 MBq (99m)Tc-DTPA-succinyl-polylysine (2 microg; DTPA is diethylenetr

285 the apparent distribution volume of (99m)Tc-DTPA.

286 beled diethylenetriaminepentaacetic acid (Tc-DTPA).

287 ioactivity after intravenous injection of Tc-DTPA represents an accurate, fast, and convenient way to

288 The rate of clearance of Tc-DTPA was measured as the slope (kappa) of the natural lo

289 ific (diethylenetriamine pentaacetate-tetra [DTPA]-A20FMDV2) or control (DTPA-A20FMDVran) peptide by

290 the first relapse (9.0 vs 2.7, P = .03) than DTPA-Gd, which also correlated well with the presence an

291 rescent enhancement observed thus far in the DTPA-type metal complexes.

292 ed mass and that of the stoichiometry of the DTPA attached per IgG increased as more DTPA was attache

293 d IgG divided by the molecular weight of the DTPA derivative.

294 JVZ-007 was successfully conjugated to DTPA for radiolabeling with (111)In at room temperature.

295 bclinical inflammatory lesions compared with DTPA-Gd, including in cases in which there was no eviden

296 -brain barrier (BBB) breakdown detected with DTPA-Gd enhancement.

297 Treatment with DTPA further reduced ascorbate radical signals to below

298 SKBr3 cells were incubated with (DTPA)(n)-trastuzumab-(IRDye800)(m) or IRDye800CW or pret

299 h excess trastuzumab before incubation with (DTPA)(n)-trastuzumab-(IRDye800)(m) abolished this bindin

300 Soil Zn application increased Zn-DTPA concentration 3.7- to 5.6-times depending on the Zn